{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T11:05:04Z","timestamp":1794049504838,"version":"4.8.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"publisher","award":["N42A670567"],"award-info":[{"award-number":["N42A670567"]}],"id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Thailand Science research and Innovation Fund Chulalongkorn University","award":["HEA-FF-68-375-3300-022"],"award-info":[{"award-number":["HEA-FF-68-375-3300-022"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The regulation of the mammalian target of rapamycin (mTOR) protein by cancer cells can lead to uncontrol of cancer cell growth and cancer therapy resistance. The drug discovery of the anticancer agent 5-(3-hydroxy-4-methoxyphenethyl)-2-methoxy-3-methylphenol (SM-3), a derivative of resveratrol by substituting a methyl group at the hydroxy group of ring A and adding a methoxy group at the para position of ring B, shows promising potential for targeting autophagy to induce cell death and suppress cancer stem cells (CSCs) through the inhibition of the mTOR protein. In human lung cancer cells, SM-3 showed greater efficacy, with lower IC<jats:sub>50<\/jats:sub> values of 72.74\u2009\u00b1\u20090.13, 67.66\u2009\u00b1\u20090.10, and 43.24\u2009\u00b1\u20090.11 \u00b5M in A549, H292, and H460 cells, respectively, compared to the parent compound, Resveratrol (Res). Moreover, the selectivity index (SI) values for BEAS2B cells compared to tumor cells treated with SM-3 were 10.99, 11.81, and 18.49 for A549, H292, and H460 cell lines, respectively. Therefore, SM-3 treatment led to reduced proliferation rates and colony formation in lung cancer cells. In our study, spheroids treated with SM-3 showed a higher proportion of dead spheroids compared to those treated with Res. Additionally, SM-3 treatment resulted in decreased expression of stem cell markers (CD133, CD44, and ALDH1A1) and transcription factors (OCT4, NANOG, and SOX2) in spheroids and organoids from human lung cancer cells by inhibiting the mTOR\/pAkt pathway. SM-3 was also found to induce autophagic cell death, as indicated by Monodansylcadaverine staining, acidic vesicle formation, and the conversion of LC3BI to LC3BII. Using MM\/GBSA calculations, SM-3 exhibited a stronger binding affinity (-25.09\u00a0kcal\/mol) compared to Res (-18.85\u00a0kcal\/mol). SM-3 also displayed greater stability during the entire simulation, maintaining lower RMSD values of 2\u20133 \u00c5 even after 80 ns. In summary, the introduction of methyl and methoxy functional groups on Res to create SM-3 effectively suppressed cancer spheroids and organoids formation in lung cancer cells by targeting the upstream mTOR\/pAkt pathway.<\/jats:p>","DOI":"10.1038\/s41598-025-98616-6","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T12:08:33Z","timestamp":1745669313000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Substituents introduction of methyl and methoxy functional groups on resveratrol stabilizes mTOR binding for autophagic cell death induction"],"prefix":"10.1038","volume":"15","author":[{"given":"Zin Zin","family":"Ei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satapat","family":"Racha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preedakorn","family":"Chunhacha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Yokoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohsuke","family":"Moriue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbin","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pithi","family":"Chanvorachote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,26]]},"reference":[{"key":"98616_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.5114\/wo.2021.103829","volume":"25","author":"KC Thandra","year":"2021","unstructured":"Thandra, K. C., Barsouk, A., Saginala, K., Aluru, J. S. & Barsouk, A. Epidemiology of lung cancer. Contemp. Oncology\/Wsp\u00f3\u0142czesna Onkologia. 25, 45\u201352 (2021).","journal-title":"Contemp. Oncology\/Wsp\u00f3\u0142czesna Onkologia"},{"key":"98616_CR2","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12964-023-01302-1","volume":"22","author":"SU Khan","year":"2024","unstructured":"Khan, S. U., Fatima, K., Aisha, S. & Malik, F. Unveiling the mechanisms and challenges of cancer drug resistance. Cell. Communication Signal. 22, 109 (2024).","journal-title":"Cell. Communication Signal."},{"key":"98616_CR3","doi-asserted-by":"crossref","unstructured":"Tufail, M. et al. Hallmarks of cancer resistance. Iscience. 27 (2024).","DOI":"10.1016\/j.isci.2024.109979"},{"key":"98616_CR4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","volume":"9","author":"B Liu","year":"2024","unstructured":"Liu, B., Zhou, H., Tan, L., Siu, K. T. H. & Guan, X. Y. Exploring treatment options in cancer: tumor treatment strategies. Signal. Transduct. Target. Therapy. 9, 175 (2024).","journal-title":"Signal. Transduct. Target. Therapy"},{"key":"98616_CR5","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41392-023-01608-z","volume":"8","author":"V Panwar","year":"2023","unstructured":"Panwar, V. et al. Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease. Signal. Transduct. Target. Therapy. 8, 375 (2023).","journal-title":"Signal. Transduct. Target. Therapy"},{"key":"98616_CR6","doi-asserted-by":"publisher","first-page":"755","DOI":"10.3390\/ijms20030755","volume":"20","author":"T Tian","year":"2019","unstructured":"Tian, T., Li, X. & Zhang, J. mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy. Int. J. Mol. Sci. 20, 755 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"98616_CR7","doi-asserted-by":"crossref","unstructured":"Murugan, A. K. in Seminars in cancer biology. 92\u2013111 (2019).","DOI":"10.1016\/j.semcancer.2019.07.003"},{"key":"98616_CR8","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2174\/138920311795659407","volume":"12","author":"H Zhou","year":"2011","unstructured":"Zhou, H. & Huang, S. Role of mTOR signaling in tumor cell motility, invasion and metastasis. Curr. Protein Pept. Sci. 12, 30\u201342 (2011).","journal-title":"Curr. Protein Pept. Sci."},{"key":"98616_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13578-020-00396-1","volume":"10","author":"Z Zou","year":"2020","unstructured":"Zou, Z., Tao, T., Li, H. & Zhu, X. mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges. Cell. Bioscience. 10, 31 (2020).","journal-title":"Cell. Bioscience"},{"key":"98616_CR10","doi-asserted-by":"crossref","unstructured":"Xie, Y., Lei, X., Zhao, G., Guo, R. & Cui, N. mTOR in programmed cell death and its therapeutic implications. Cytokine Growth Factor Rev. 71, 66-81 (2023).","DOI":"10.1016\/j.cytogfr.2023.06.002"},{"key":"98616_CR11","doi-asserted-by":"publisher","first-page":"a008813","DOI":"10.1101\/cshperspect.a008813","volume":"4","author":"G Das","year":"2012","unstructured":"Das, G., Shravage, B. V. & Baehrecke, E. H. Regulation and function of autophagy during cell survival and cell death. Cold Spring Harb. Perspect. Biol. 4, a008813 (2012).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"98616_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s40560-024-00754-y","volume":"12","author":"T Iba","year":"2024","unstructured":"Iba, T., Helms, J., Maier, C. L., Ferrer, R. & Levy, J. H. Autophagy and autophagic cell death in sepsis: friend or foe? J. Intensive Care. 12, 41 (2024).","journal-title":"J. Intensive Care"},{"key":"98616_CR13","doi-asserted-by":"crossref","unstructured":"Mizushima, N., Levine, B., Cuervo, A. M. & Klionsky, D. J. Autophagy fights disease through cellular self-digestion. nature 451, 1069\u20131075 (2008).","DOI":"10.1038\/nature06639"},{"key":"98616_CR14","doi-asserted-by":"publisher","first-page":"106695","DOI":"10.1016\/j.phrs.2023.106695","volume":"189","author":"MM Kadhim","year":"2023","unstructured":"Kadhim, M. M. et al. Autophagy as a self-digestion signal in human cancers: regulation by MicroRNAs in affecting carcinogenesis and therapy response. Pharmacol. Res. 189, 106695 (2023).","journal-title":"Pharmacol. Res."},{"key":"98616_CR15","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13045-020-01000-2","volume":"13","author":"H Chang","year":"2020","unstructured":"Chang, H. & Zou, Z. Targeting autophagy to overcome drug resistance: further developments. J. Hematol. Oncol. 13, 159 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"98616_CR16","doi-asserted-by":"publisher","first-page":"100871","DOI":"10.1016\/j.tranon.2020.100871","volume":"13","author":"Q Xie","year":"2020","unstructured":"Xie, Q., Liu, Y. & Li, X. The interaction mechanism between autophagy and apoptosis in colon cancer. Translational Oncol. 13, 100871 (2020).","journal-title":"Translational Oncol."},{"key":"98616_CR17","doi-asserted-by":"crossref","unstructured":"Su, M., Mei, Y. & Sinha, S. Role of the crosstalk between autophagy and apoptosis in cancer. Journal of oncology 102735 (2013). (2013).","DOI":"10.1155\/2013\/102735"},{"key":"98616_CR18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1042\/BCJ20220325","volume":"481","author":"A Ragupathi","year":"2024","unstructured":"Ragupathi, A., Kim, C. & Jacinto, E. The mTORC2 signaling network: targets and cross-talks. Biochem. J. 481, 45\u201391 (2024).","journal-title":"Biochem. J."},{"key":"98616_CR19","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.21037\/tlcr-20-141","volume":"9","author":"W Fang","year":"2020","unstructured":"Fang, W. et al. PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy. Translational Lung Cancer Res. 9, 1258 (2020).","journal-title":"Translational Lung Cancer Res."},{"key":"98616_CR20","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano, A. et al. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol. Cancer. 22, 138 (2023).","journal-title":"Mol. Cancer"},{"key":"98616_CR21","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41419-024-07077-8","volume":"15","author":"B Son","year":"2024","unstructured":"Son, B., Lee, W., Kim, H., Shin, H. & Park, H. H. Targeted therapy of cancer stem cells: Inhibition of mTOR in pre-clinical and clinical research. Cell Death Dis. 15, 696 (2024).","journal-title":"Cell Death Dis."},{"key":"98616_CR22","doi-asserted-by":"crossref","unstructured":"Agliano, A., Calvo, A. & Box, C. The challenge of targeting cancer stem cells to halt metastasis. Sem. Cancer Biol. 44, 25\u201342 (2017).","DOI":"10.1016\/j.semcancer.2017.03.003"},{"key":"98616_CR23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41392-020-0110-5","volume":"5","author":"L Yang","year":"2020","unstructured":"Yang, L. et al. Targeting cancer stem cell pathways for cancer therapy. Signal. Transduct. Target. Therapy. 5, 8 (2020).","journal-title":"Signal. Transduct. Target. Therapy"},{"key":"98616_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40169-018-0198-1","volume":"7","author":"PM Glumac","year":"2018","unstructured":"Glumac, P. M. & LeBeau, A. M. The role of CD133 in cancer: a concise review. Clin. Translational Med. 7, 1\u201314 (2018).","journal-title":"Clin. Translational Med."},{"key":"98616_CR25","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.3892\/mmr.2013.1667","volume":"8","author":"H Le","year":"2013","unstructured":"Le, H., Zeng, F., Xu, L., Liu, X. & Huang, Y. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer. Mol. Med. Rep. 8, 1511\u20131518 (2013).","journal-title":"Mol. Med. Rep."},{"key":"98616_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-018-0605-5","volume":"11","author":"C Chen","year":"2018","unstructured":"Chen, C., Zhao, S., Karnad, A. & Freeman, J. W. The biology and role of CD44 in cancer progression: therapeutic implications. J. Hematol. Oncol. 11, 1\u201323 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"98616_CR27","doi-asserted-by":"crossref","unstructured":"Tian, Y., Song, W., Li, D., Cai, L. & Zhao, Y. Resveratrol as a natural regulator of autophagy for prevention and treatment of cancer. OncoTargets Therapy 12, 8601\u20138609 (2019).","DOI":"10.2147\/OTT.S213043"},{"key":"98616_CR28","doi-asserted-by":"publisher","first-page":"5154","DOI":"10.3390\/molecules27165154","volume":"27","author":"RA Bohara","year":"2022","unstructured":"Bohara, R. A. et al. Recent overview of Resveratrol\u2019s beneficial effects and its nano-delivery systems. Molecules 27, 5154 (2022).","journal-title":"Molecules"},{"key":"98616_CR29","doi-asserted-by":"publisher","first-page":"126087","DOI":"10.1016\/j.molliq.2024.126087","volume":"414","author":"Q Liu","year":"2024","unstructured":"Liu, Q. et al. Encapsulation of Resveratrol with acyclic cucurbit [n] urils: characterization\/stability enhancement\/antioxidant efficacy\/anticancer activity. J. Mol. Liq. 414, 126087 (2024).","journal-title":"J. Mol. Liq."},{"key":"98616_CR30","doi-asserted-by":"publisher","first-page":"103719","DOI":"10.1016\/j.bioorg.2020.103719","volume":"98","author":"M Yousuf","year":"2020","unstructured":"Yousuf, M., Jinka, S., Adhikari, S. S. & Banerjee, R. Methoxy-enriched cationic Stilbenes as anticancer therapeutics. Bioorg. Chem. 98, 103719 (2020).","journal-title":"Bioorg. Chem."},{"key":"98616_CR31","first-page":"569","volume":"16","author":"M Salla","year":"2024","unstructured":"Salla, M. et al. Enhancing the bioavailability of Resveratrol: combine it, derivatize it. or. Encapsulate It? Pharm. 16, 569 (2024).","journal-title":"or. Encapsulate It? Pharm."},{"key":"98616_CR32","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s12906-023-04016-6","volume":"23","author":"S Thongsom","year":"2023","unstructured":"Thongsom, S. et al. Structural modification of Resveratrol analogue exhibits anticancer activity against lung cancer stem cells via suppression of Akt signaling pathway. BMC Complement. Med. Ther. 23, 183 (2023).","journal-title":"BMC Complement. Med. Ther."},{"key":"98616_CR33","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.tetlet.2015.12.110","volume":"57","author":"R Tanifuji","year":"2016","unstructured":"Tanifuji, R. et al. Catalytic asymmetric synthesis of the common amino acid component in the biosynthesis of tetrahydroisoquinoline alkaloids. Tetrahedron Lett. 57, 623\u2013626 (2016).","journal-title":"Tetrahedron Lett."},{"key":"98616_CR34","doi-asserted-by":"publisher","first-page":"8268","DOI":"10.3390\/molecules27238268","volume":"27","author":"B Innets","year":"2022","unstructured":"Innets, B. et al. Akt\/mTOR targeting activity of Resveratrol derivatives in non-small lung cancer. Molecules 27, 8268 (2022).","journal-title":"Molecules"},{"key":"98616_CR35","doi-asserted-by":"publisher","first-page":"21772","DOI":"10.1038\/srep21772","volume":"6","author":"D Park","year":"2016","unstructured":"Park, D. et al. Resveratrol induces autophagy by directly inhibiting mTOR through ATP competition. Sci. Rep. 6, 21772. https:\/\/doi.org\/10.1038\/srep21772 (2016).","journal-title":"Sci. Rep."},{"key":"98616_CR36","doi-asserted-by":"crossref","unstructured":"Borsari, C., De Pascale, M. & Wymann, M. P. Chemical and Structural Strategies to Selectively Target mTOR Kinase. ChemMedChem 16, 2744\u20132759 (2021).","DOI":"10.1002\/cmdc.202100332"},{"key":"98616_CR37","doi-asserted-by":"publisher","first-page":"114498","DOI":"10.1016\/j.ejmech.2022.114498","volume":"238","author":"P Oleksak","year":"2022","unstructured":"Oleksak, P. et al. Contemporary mTOR inhibitor scaffolds to diseases breakdown: A patent review (2015\u20132021). Eur. J. Med. Chem. 238, 114498 (2022).","journal-title":"Eur. J. Med. Chem."},{"key":"98616_CR38","doi-asserted-by":"publisher","first-page":"25227","DOI":"10.1074\/jbc.M114.554881","volume":"289","author":"HC Dan","year":"2014","unstructured":"Dan, H. C. et al. Akt-dependent activation of mTORC1 complex involves phosphorylation of mTOR (mammalian target of rapamycin) by I\u03baB kinase \u03b1 (IKK\u03b1). J. Biol. Chem. 289, 25227\u201325240 (2014).","journal-title":"J. Biol. Chem."},{"key":"98616_CR39","doi-asserted-by":"crossref","unstructured":"Lee, S. Y., Koo, I. S., Hwang, H. J. & Lee, D. W. In vitro three-dimensional (3D) cell culture tools for spheroid and organoid models. SLAS Discovery. 28, 119-137 (2023).","DOI":"10.1016\/j.slasd.2023.03.006"},{"key":"98616_CR40","doi-asserted-by":"publisher","first-page":"dev152595","DOI":"10.1242\/dev.152595","volume":"145","author":"D Meng","year":"2018","unstructured":"Meng, D., Frank, A. R. & Jewell, J. L. mTOR signaling in stem and progenitor cells. Development 145, dev152595 (2018).","journal-title":"Development"},{"issue":"1","key":"98616_CR41","first-page":"19","volume":"63","author":"A Barrientos","year":"2009","unstructured":"Barrientos, A., Fontanesi, F. & D\u00edaz, F. Evaluation of the mitochondrial respiratory chain and oxidative phosphorylation system using polarography and spectrophotometric enzyme assays. Curr. Protocols Hum. Genet. 63 (1), 19\u201313 (2009).","journal-title":"Curr. Protocols Hum. Genet."},{"key":"98616_CR42","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3892\/ijmm.2022.5182","volume":"50","author":"Y Yin","year":"2022","unstructured":"Yin, Y. & Shen, H. Common methods in mitochondrial research. Int. J. Mol. Med. 50, 126 (2022).","journal-title":"Int. J. Mol. Med."},{"key":"98616_CR43","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.3390\/ijms18122589","volume":"18","author":"JH Ko","year":"2017","unstructured":"Ko, J. H. et al. The role of Resveratrol in cancer therapy. Int. J. Mol. Sci. 18, 2589 (2017).","journal-title":"Int. J. Mol. Sci."},{"key":"98616_CR44","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3390\/biom10010138","volume":"10","author":"SK Liew","year":"2020","unstructured":"Liew, S. K., Malagobadan, S., Arshad, N. M. & Nagoor, N. H. A review of the structure\u2014activity relationship of natural and synthetic antimetastatic compounds. Biomolecules 10, 138 (2020).","journal-title":"Biomolecules"},{"key":"98616_CR45","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/j.bmc.2009.11.066","volume":"18","author":"BP Bandgar","year":"2010","unstructured":"Bandgar, B. P., Gawande, S. S., Bodade, R. G., Totre, J. V. & Khobragade, C. N. Synthesis and biological evaluation of simple methoxylated Chalcones as anticancer, anti-inflammatory and antioxidant agents. Bioorg. Med. Chem. 18, 1364\u20131370 (2010).","journal-title":"Bioorg. Med. Chem."},{"key":"98616_CR46","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41586-023-05905-z","volume":"616","author":"AV Sadybekov","year":"2023","unstructured":"Sadybekov, A. V. & Katritch, V. Computational approaches streamlining drug discovery. Nature 616, 673\u2013685 (2023).","journal-title":"Nature"},{"key":"98616_CR47","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.3762\/bjoc.12.267","volume":"12","author":"SP Leelananda","year":"2016","unstructured":"Leelananda, S. P. & Lindert, S. Computational methods in drug discovery. Beilstein J. Org. Chem. 12, 2694\u20132718 (2016).","journal-title":"Beilstein J. Org. Chem."},{"key":"98616_CR48","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1021\/acs.jcim.2c00601","volume":"62","author":"E Akkus","year":"2022","unstructured":"Akkus, E., Tayfuroglu, O., Yildiz, M. & Kocak, A. Accurate binding free energy method from end-state MD simulations. J. Chem. Inf. Model. 62, 4095\u20134106 (2022).","journal-title":"J. Chem. Inf. Model."},{"key":"98616_CR49","doi-asserted-by":"publisher","first-page":"712085","DOI":"10.3389\/fmolb.2021.712085","volume":"8","author":"E King","year":"2021","unstructured":"King, E., Aitchison, E., Li, H. & Luo, R. Recent developments in free energy calculations for drug discovery. Front. Mol. Biosci. 8, 712085 (2021).","journal-title":"Front. Mol. Biosci."},{"key":"98616_CR50","doi-asserted-by":"publisher","first-page":"14190","DOI":"10.1074\/jbc.M111.219923","volume":"286","author":"YT Wu","year":"2011","unstructured":"Wu, Y. T. et al. mTOR complex 2 targets Akt for proteasomal degradation via phosphorylation at the hydrophobic motif. J. Biol. Chem. 286, 14190\u201314198 (2011).","journal-title":"J. Biol. Chem."},{"key":"98616_CR51","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1152\/physrev.00026.2020","volume":"101","author":"A Szwed","year":"2021","unstructured":"Szwed, A., Kim, E. & Jacinto, E. Regulation and metabolic functions of mTORC1 and mTORC2. Physiol. Rev. 101, 1371\u20131426 (2021).","journal-title":"Physiol. Rev."},{"key":"98616_CR52","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1039\/D3SC04690G","volume":"15","author":"Y Liu","year":"2024","unstructured":"Liu, Y., Zhang, M., Jang, H. & Nussinov, R. The allosteric mechanism of mTOR activation can inform bitopic inhibitor optimization. Chem. Sci. 15, 1003\u20131017 (2024).","journal-title":"Chem. Sci."},{"key":"98616_CR53","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/s41589-021-00813-7","volume":"17","author":"BJ Lee","year":"2021","unstructured":"Lee, B. J. et al. Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth. Nat. Chem. Biol. 17, 1065\u20131074 (2021).","journal-title":"Nat. Chem. Biol."},{"key":"98616_CR54","doi-asserted-by":"publisher","first-page":"e79795","DOI":"10.1371\/journal.pone.0079795","volume":"9","author":"M Matsuda-Lennikov","year":"2014","unstructured":"Matsuda-Lennikov, M. et al. Lysosomal interaction of Akt with Phafin2: a critical step in the induction of autophagy. PloS One. 9, e79795 (2014).","journal-title":"PloS One"},{"key":"98616_CR55","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41392-024-01851-y","volume":"9","author":"X Chu","year":"2024","unstructured":"Chu, X. et al. Cancer stem cells: advances in knowledge and implications for cancer therapy. Signal. Transduct. Target. Therapy. 9, 170 (2024).","journal-title":"Signal. Transduct. Target. Therapy"},{"key":"98616_CR56","doi-asserted-by":"publisher","first-page":"4846","DOI":"10.3390\/cancers15194846","volume":"15","author":"P Nayak","year":"2023","unstructured":"Nayak, P., Bentivoglio, V., Varani, M. & Signore, A. Three-dimensional in vitro tumor spheroid models for evaluation of anticancer therapy: recent updates. Cancers 15, 4846 (2023).","journal-title":"Cancers"},{"key":"98616_CR57","first-page":"4931","volume":"11","author":"A Radajewska","year":"2021","unstructured":"Radajewska, A. et al. Three dimensional in vitro culture systems in anticancer drug discovery targeted on cancer stem cells. Am. J. cancer Res. 11, 4931 (2021).","journal-title":"Am. J. cancer Res."},{"key":"98616_CR58","doi-asserted-by":"publisher","first-page":"740574","DOI":"10.3389\/fcell.2021.740574","volume":"9","author":"Y Huang","year":"2021","unstructured":"Huang, Y. et al. Research progress, challenges, and breakthroughs of organoids as disease models. Front. Cell. Dev. Biology. 9, 740574 (2021).","journal-title":"Front. Cell. Dev. Biology"},{"key":"98616_CR59","doi-asserted-by":"publisher","first-page":"10131","DOI":"10.3390\/ijms241210131","volume":"24","author":"I Monle\u00f3n-Guinot","year":"2023","unstructured":"Monle\u00f3n-Guinot, I. et al. Morphological characterization of human lung cancer organoids cultured in type i collagen hydrogels: a histological approach. Int. J. Mol. Sci. 24, 10131 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"98616_CR60","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","volume":"7","author":"A Daina","year":"2017","unstructured":"Daina, A., Michielin, O. & Zoete, V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 7, 42717 (2017).","journal-title":"Sci. Rep."},{"key":"98616_CR61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0169-409X(00)00129-0","volume":"46","author":"CA Lipinski","year":"2001","unstructured":"Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. C. A. S. 528: DC% 2BD3MXitVOhs7o% 3D: experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv Rev. 46, 1\u20133 (2001).","journal-title":"Adv. Drug Deliv Rev."},{"key":"98616_CR62","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1021\/acschembio.7b00903","volume":"13","author":"JB Baell","year":"2018","unstructured":"Baell, J. B. & Nissink, J. W. M. Seven year itch: Pan-Assay interference compounds (PAINS) in 2017-Utility and limitations. ACS Chem. Biol. 13, 36\u201344 (2018).","journal-title":"ACS Chem. Biol."},{"key":"98616_CR63","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature12122","volume":"497","author":"H Yang","year":"2013","unstructured":"Yang, H. et al. mTOR kinase structure, mechanism and regulation. Nature 497, 217\u2013223 (2013).","journal-title":"Nature"},{"key":"98616_CR64","doi-asserted-by":"publisher","first-page":"D488","DOI":"10.1093\/nar\/gkac1077","volume":"51","author":"SK Burley","year":"2023","unstructured":"Burley, S. K. et al. RCSB protein data bank (RCSB. org): delivery of experimentally-determined PDB structures alongside one million computed structure models of proteins from artificial intelligence\/machine learning. Nucleic Acids Res. 51, D488\u2013D508 (2023).","journal-title":"Nucleic Acids Res."},{"key":"98616_CR65","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"EF Pettersen","year":"2004","unstructured":"Pettersen, E. F. et al. UCSF Chimera\u2014a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605\u20131612 (2004).","journal-title":"J. Comput. Chem."},{"key":"98616_CR66","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1002\/jcc.26700","volume":"42","author":"AJ Schaefer","year":"2021","unstructured":"Schaefer, A. J., Ingman, V. M. & Wheeler, S. E. SEQCROW: A chimerax bundle to facilitate quantum chemical applications to complex molecular systems. J. Comput. Chem. 42, 1750\u20131754 (2021).","journal-title":"J. Comput. Chem."},{"key":"98616_CR67","unstructured":"Frisch, M. et al. Gaussian 09 (Revision A02). Gaussian Inc Wallingford CT (2009)."},{"key":"98616_CR68","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1002\/jcc.10128","volume":"23","author":"A Jakalian","year":"2002","unstructured":"Jakalian, A., Jack, D. B. & Bayly, C. I. Fast, efficient generation of high-quality atomic charges. AM1\u2010BCC model: II. Parameterization and validation. J. Comput. Chem. 23, 1623\u20131641 (2002).","journal-title":"J. Comput. Chem."},{"key":"98616_CR69","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/(SICI)1096-987X(20000130)21:2<132::AID-JCC5>3.0.CO;2-P","volume":"21","author":"A Jakalian","year":"2000","unstructured":"Jakalian, A., Bush, B. L., Jack, D. B. & Bayly, C. I. Fast, efficient generation of high-quality atomic charges. AM1\u2010BCC model: I. Method. J. Comput. Chem. 21, 132\u2013146 (2000).","journal-title":"J. Comput. Chem."},{"key":"98616_CR70","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1002\/jcc.26993","volume":"43","author":"LE Prentis","year":"2022","unstructured":"Prentis, L. E., Singleton, C. D., Bickel, J. D., Allen, W. J. & Rizzo, R. C. A molecular evolution algorithm for ligand design in DOCK. J. Comput. Chem. 43, 1942\u20131963 (2022).","journal-title":"J. Comput. Chem."},{"key":"98616_CR71","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1021\/ci200227u","volume":"51","author":"RA Laskowski","year":"2011","unstructured":"Laskowski, R. A., Swindells, M. B. & LigPlot+ Multiple Ligand\u2013Protein interaction diagrams for drug discovery. J. Chem. Inf. Model. 51, 2778\u20132786 (2011).","journal-title":"J. Chem. Inf. Model."},{"key":"98616_CR72","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/pro.3943","volume":"30","author":"EF Pettersen","year":"2021","unstructured":"Pettersen, E. F. et al. UCSF chimerax: structure visualization for researchers, educators, and developers. Protein Sci. 30, 70\u201382 (2021).","journal-title":"Protein Sci."},{"key":"98616_CR73","unstructured":"Case, D. et al. AmberReference Manual 2018 (2018)."},{"key":"98616_CR74","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1021\/acs.jctc.5b00255","volume":"11","author":"JA Maier","year":"2015","unstructured":"Maier, J. A. et al. ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB. J. Chem. Theory Comput. 11, 3696\u20133713 (2015).","journal-title":"J. Chem. Theory Comput."},{"key":"98616_CR75","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1002\/jcc.20035","volume":"25","author":"J Wang","year":"2004","unstructured":"Wang, J., Wolf, R. M., Caldwell, J. W., Kollman, P. A. & Case, D. A. Development and testing of a general amber force field. J. Comput. Chem. 25, 1157\u20131174 (2004).","journal-title":"J. Comput. Chem."},{"key":"98616_CR76","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1016\/j.bmcl.2017.05.020","volume":"27","author":"TD McGee Jr","year":"2017","unstructured":"McGee Jr, T. D., Yi, H. A., Allen, W. J., Jacobs, A. & Rizzo, R. C. Structure-based identification of inhibitors targeting obstruction of the HIVgp41 N-heptad repeat trimer. Bioorg. Med. Chem. Lett. 27, 3177\u20133184 (2017).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"98616_CR77","doi-asserted-by":"publisher","first-page":"4304","DOI":"10.1021\/acs.biochem.9b00625","volume":"58","author":"Y Zhou","year":"2019","unstructured":"Zhou, Y. et al. Identification of fatty acid binding protein 5 inhibitors through similarity-based screening. Biochemistry 58, 4304\u20134316 (2019).","journal-title":"Biochemistry"},{"key":"98616_CR78","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1021\/ct400341p","volume":"9","author":"DR Roe","year":"2013","unstructured":"Roe, D. R. & Cheatham, T. E. III PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data. J. Chem. Theory Comput. 9, 3084\u20133095 (2013).","journal-title":"J. Chem. Theory Comput."},{"key":"98616_CR79","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1021\/ct300418h","volume":"8","author":"III Miller","year":"2012","unstructured":"Miller, I. I. I. MMPBSA. Py: an efficient program for end-state free energy calculations. J. Chem. Theory Comput. 8, 3314\u20133321 (2012).","journal-title":"J. Chem. Theory Comput."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-98616-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-98616-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-98616-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T13:03:32Z","timestamp":1745672612000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-98616-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,26]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["98616"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-98616-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,26]]},"assertion":[{"value":"15 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14675"}}